US20030220341A1 - Chemokine receptor binding heterocyclic compounds with enhanced efficacy - Google Patents
Chemokine receptor binding heterocyclic compounds with enhanced efficacy Download PDFInfo
- Publication number
- US20030220341A1 US20030220341A1 US10/329,329 US32932902A US2003220341A1 US 20030220341 A1 US20030220341 A1 US 20030220341A1 US 32932902 A US32932902 A US 32932902A US 2003220341 A1 US2003220341 A1 US 2003220341A1
- Authority
- US
- United States
- Prior art keywords
- mmol
- compound
- solution
- stirred
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *.B.C.[1*]C1=C([1*])[Y]=C2C(=*1)CCCC2N(CC=CCC)CC1=NC([4*])=C([4*])N1[3*] Chemical compound *.B.C.[1*]C1=C([1*])[Y]=C2C(=*1)CCCC2N(CC=CCC)CC1=NC([4*])=C([4*])N1[3*] 0.000 description 11
- APTKWRUWXZCWES-MKAMJTKASA-N N[C@H]1CC[C@H](N(CC2=NC3=CC=CC=C3N2)C2CCCC3=CC=CN=C32)CC1 Chemical compound N[C@H]1CC[C@H](N(CC2=NC3=CC=CC=C3N2)C2CCCC3=CC=CN=C32)CC1 APTKWRUWXZCWES-MKAMJTKASA-N 0.000 description 4
- MBYTYGQMQYOHJU-FWMLTEASSA-N C.C.C.O=C1C2=C(C=CC=C2)C(=O)N1C/C=C/CN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound C.C.C.O=C1C2=C(C=CC=C2)C(=O)N1C/C=C/CN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 MBYTYGQMQYOHJU-FWMLTEASSA-N 0.000 description 2
- KJFLXTAGPKTQEP-UHFFFAOYSA-N C.C.NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCOC2=CC=CN=C21 Chemical compound C.C.NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCOC2=CC=CN=C21 KJFLXTAGPKTQEP-UHFFFAOYSA-N 0.000 description 2
- KRWWXVXIVXDMFI-UHFFFAOYSA-N C1=CN=C2C(=C1)CCCC2N(CC1=NC2=C(C=CC=C2)N1)CC1CCNCC1 Chemical compound C1=CN=C2C(=C1)CCCC2N(CC1=NC2=C(C=CC=C2)N1)CC1CCNCC1 KRWWXVXIVXDMFI-UHFFFAOYSA-N 0.000 description 2
- CSOCKIJAJOGZII-UHFFFAOYSA-N C1=CN=C2C(=C1)CCCC2NCCN1C=CN=C1 Chemical compound C1=CN=C2C(=C1)CCCC2NCCN1C=CN=C1 CSOCKIJAJOGZII-UHFFFAOYSA-N 0.000 description 2
- KCBSQAZASDDGRZ-SANMLTNESA-N C=CCN1C(CN(CCCCNC(=O)C2=C(Cl)C=NC=C2Cl)[C@H]2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 Chemical compound C=CCN1C(CN(CCCCNC(=O)C2=C(Cl)C=NC=C2Cl)[C@H]2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 KCBSQAZASDDGRZ-SANMLTNESA-N 0.000 description 2
- NPHCJGXGOTYRFT-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=NC(CCCO)=C1 Chemical compound CC(C)(C)OC(=O)N1C=NC(CCCO)=C1 NPHCJGXGOTYRFT-UHFFFAOYSA-N 0.000 description 2
- OWNIGLWHXOENAA-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)OCCNC(=O)OC(C)(C)C)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)OCCNC(=O)OC(C)(C)C)C=C1 OWNIGLWHXOENAA-UHFFFAOYSA-N 0.000 description 2
- PONXFPKVSZKTQC-UHFFFAOYSA-N CCCN1C=CN=C1CN(CCCCN)C1CCCC2=C1N=CC=C2 Chemical compound CCCN1C=CN=C1CN(CCCCN)C1CCCC2=C1N=CC=C2 PONXFPKVSZKTQC-UHFFFAOYSA-N 0.000 description 2
- MNSORORLFIHBNN-VHEBQXMUSA-N CCOC(=O)/C=C/C1=NC=CN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CCOC(=O)/C=C/C1=NC=CN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 MNSORORLFIHBNN-VHEBQXMUSA-N 0.000 description 2
- JVTBUMILAUPKSZ-PBVHZTIHSA-N CN(C)[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 Chemical compound CN(C)[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 JVTBUMILAUPKSZ-PBVHZTIHSA-N 0.000 description 2
- OQCVCCDCGRTKFB-UHFFFAOYSA-N CN1C(CN(CCCCN)C2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 Chemical compound CN1C(CN(CCCCN)C2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 OQCVCCDCGRTKFB-UHFFFAOYSA-N 0.000 description 2
- PHKYBRBEKSGLMH-UHFFFAOYSA-N CN1C(CNC2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 Chemical compound CN1C(CNC2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 PHKYBRBEKSGLMH-UHFFFAOYSA-N 0.000 description 2
- BVNNURLSEBLPOJ-FQEVSTJZSA-N NCC(=CCN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21)CN Chemical compound NCC(=CCN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21)CN BVNNURLSEBLPOJ-FQEVSTJZSA-N 0.000 description 2
- GDTKLNBGYSEWBO-UHFFFAOYSA-N NCCCCN(CC1=NC2=CC(F)=CC=C2N1)C1CCCC2=C1N=CC=C2 Chemical compound NCCCCN(CC1=NC2=CC(F)=CC=C2N1)C1CCCC2=C1N=CC=C2 GDTKLNBGYSEWBO-UHFFFAOYSA-N 0.000 description 2
- ULWZFUFCZKWHLB-UHFFFAOYSA-N O=C(C1=C(Cl)C=NC=C1Cl)N1CCCC(CNC2CCCC3=CC=CN=C32)C1 Chemical compound O=C(C1=C(Cl)C=NC=C1Cl)N1CCCC(CNC2CCCC3=CC=CN=C32)C1 ULWZFUFCZKWHLB-UHFFFAOYSA-N 0.000 description 2
- WVLHHLRVNDMIAR-IBGZPJMESA-N [H][C@]1(N(CCCCN)CC2=NC3=C(C=CC=C3)N2)CCCC2=CC=CN=C21 Chemical compound [H][C@]1(N(CCCCN)CC2=NC3=C(C=CC=C3)N2)CCCC2=CC=CN=C21 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 description 2
- WXJLDBAHRDFMAZ-ROAUJZCXSA-N Br.Br.Br.Br.Br.Br.N[C@H]1C=C[C@H](N(CC2=NC3=C(C=CC=C3)N2)[C@@H]2CCCC3=CC=CN=C32)CC1.N[C@H]1C=C[C@H](N(CC2=NC3=C(C=CC=C3)N2)[C@H]2CCCC3=CC=CN=C32)CC1 Chemical compound Br.Br.Br.Br.Br.Br.N[C@H]1C=C[C@H](N(CC2=NC3=C(C=CC=C3)N2)[C@@H]2CCCC3=CC=CN=C32)CC1.N[C@H]1C=C[C@H](N(CC2=NC3=C(C=CC=C3)N2)[C@H]2CCCC3=CC=CN=C32)CC1 WXJLDBAHRDFMAZ-ROAUJZCXSA-N 0.000 description 1
- JCGJRVXCYWBTJF-OCXYKCRISA-N Br.Br.Br.C.CCCCN[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 Chemical compound Br.Br.Br.C.CCCCN[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 JCGJRVXCYWBTJF-OCXYKCRISA-N 0.000 description 1
- JOBBHBIDUHNUSU-UHFFFAOYSA-N Br.C.C.CC1=CC2=C(C=C1C)NC(CN(CCCCN)C1CCCC3=CC=CN=C31)=N2 Chemical compound Br.C.C.CC1=CC2=C(C=C1C)NC(CN(CCCCN)C1CCCC3=CC=CN=C31)=N2 JOBBHBIDUHNUSU-UHFFFAOYSA-N 0.000 description 1
- GWGIXMSBBUOUBK-UHFFFAOYSA-N Br.C.C.NCCCCN(CC1=NC2=C(C=CC=C2F)N1)C1CCCC2=CC=CN=C21 Chemical compound Br.C.C.NCCCCN(CC1=NC2=C(C=CC=C2F)N1)C1CCCC2=CC=CN=C21 GWGIXMSBBUOUBK-UHFFFAOYSA-N 0.000 description 1
- OEDXLKQJTXFIMT-UHFFFAOYSA-N C(CCN(Cc1nc2ccccc2[nH]1)C1c2ncccc2CCC1)CNCc1ncccn1 Chemical compound C(CCN(Cc1nc2ccccc2[nH]1)C1c2ncccc2CCC1)CNCc1ncccn1 OEDXLKQJTXFIMT-UHFFFAOYSA-N 0.000 description 1
- COSOSDQDQWXLKC-UHFFFAOYSA-N C.C.C.C=C(CCN)CN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound C.C.C.C=C(CCN)CN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 COSOSDQDQWXLKC-UHFFFAOYSA-N 0.000 description 1
- WEMJAQAGMXTCEW-VLEZWVESSA-N C.C.C.CC1=CC=CC2=C1N=C(CN(CCCCN)[C@H]1CCCC3=CC=CN=C31)N2 Chemical compound C.C.C.CC1=CC=CC2=C1N=C(CN(CCCCN)[C@H]1CCCC3=CC=CN=C31)N2 WEMJAQAGMXTCEW-VLEZWVESSA-N 0.000 description 1
- WEMJAQAGMXTCEW-UHFFFAOYSA-N C.C.C.CC1=CC=CC2=C1NC(CN(CCCCN)C1CCCC3=CC=CN=C31)=N2 Chemical compound C.C.C.CC1=CC=CC2=C1NC(CN(CCCCN)C1CCCC3=CC=CN=C31)=N2 WEMJAQAGMXTCEW-UHFFFAOYSA-N 0.000 description 1
- FUUJIVKBPOPFCL-UHFFFAOYSA-N C.C.C.COC1=CC=CC2=C1N=C(CN(CCCCN)C1CCCC3=C1N=CC=C3)N2 Chemical compound C.C.C.COC1=CC=CC2=C1N=C(CN(CCCCN)C1CCCC3=C1N=CC=C3)N2 FUUJIVKBPOPFCL-UHFFFAOYSA-N 0.000 description 1
- OTPVMYHMINOPPD-UHFFFAOYSA-N C.C.C.COC1=CC=NC2=C1CCCC2N(CCCCN)CC1=NC2=C(C=CC=C2)N1 Chemical compound C.C.C.COC1=CC=NC2=C1CCCC2N(CCCCN)CC1=NC2=C(C=CC=C2)N1 OTPVMYHMINOPPD-UHFFFAOYSA-N 0.000 description 1
- YGAQFAHSVJCYJW-FHJHGPAASA-N C.C.C.NC/C=C/CN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound C.C.C.NC/C=C/CN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 YGAQFAHSVJCYJW-FHJHGPAASA-N 0.000 description 1
- YGAQFAHSVJCYJW-FGSKAQBVSA-N C.C.C.NC/C=C\CN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound C.C.C.NC/C=C\CN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 YGAQFAHSVJCYJW-FGSKAQBVSA-N 0.000 description 1
- YGAQFAHSVJCYJW-XFAPBMPQSA-N C.C.C.NC/C=C\CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21.[H]Cl.[H]Cl.[H]Cl Chemical compound C.C.C.NC/C=C\CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21.[H]Cl.[H]Cl.[H]Cl YGAQFAHSVJCYJW-XFAPBMPQSA-N 0.000 description 1
- MGBWAGDKQYGBNJ-UHFFFAOYSA-N C.C.C.NCC(=CCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=CC=CN=C21)CN Chemical compound C.C.C.NCC(=CCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=CC=CN=C21)CN MGBWAGDKQYGBNJ-UHFFFAOYSA-N 0.000 description 1
- SNINJLNACLCOEK-UHFFFAOYSA-N C.C.C.NCCC1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 Chemical compound C.C.C.NCCC1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 SNINJLNACLCOEK-UHFFFAOYSA-N 0.000 description 1
- OILIPBVVQPRERQ-UHFFFAOYSA-N C.C.C.NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1NC=N2 Chemical compound C.C.C.NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1NC=N2 OILIPBVVQPRERQ-UHFFFAOYSA-N 0.000 description 1
- LEEKTMYNFWMQMB-UHFFFAOYSA-N C.C.C.NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=C(Cl)N=C21 Chemical compound C.C.C.NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=C(Cl)N=C21 LEEKTMYNFWMQMB-UHFFFAOYSA-N 0.000 description 1
- JSPMOUODDKEQGH-UHFFFAOYSA-N C.C.C.NCCCCN(CC1=NC2=C(CCCC2)N1)C1CCCC2=CC=CN=C21 Chemical compound C.C.C.NCCCCN(CC1=NC2=C(CCCC2)N1)C1CCCC2=CC=CN=C21 JSPMOUODDKEQGH-UHFFFAOYSA-N 0.000 description 1
- QXSKNFUTZIBYFN-UHFFFAOYSA-N C.C.C.[H]C(CN)(CCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1N=CC=C2)OC Chemical compound C.C.C.[H]C(CN)(CCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1N=CC=C2)OC QXSKNFUTZIBYFN-UHFFFAOYSA-N 0.000 description 1
- LJTMSLQWHOBCJN-KOWHYRDCSA-N C.C.C.[H]C1(N(C/C=C(\C)CN)CC2=NC3=C(C=CC=C3)N2)CCCC2=CC=CN=C21 Chemical compound C.C.C.[H]C1(N(C/C=C(\C)CN)CC2=NC3=C(C=CC=C3)N2)CCCC2=CC=CN=C21 LJTMSLQWHOBCJN-KOWHYRDCSA-N 0.000 description 1
- PIFJGGNEGHZKRZ-UHFFFAOYSA-N C.C.C.[H]C1(N(CCC(=C)CN)CC2=NC3=C(C=CC=C3)N2)CCCC2=CC=CN=C21 Chemical compound C.C.C.[H]C1(N(CCC(=C)CN)CC2=NC3=C(C=CC=C3)N2)CCCC2=CC=CN=C21 PIFJGGNEGHZKRZ-UHFFFAOYSA-N 0.000 description 1
- UYSVMYHBLFFIEB-UHFFFAOYSA-N C.C.C.[H]C1(N(CCC2(CN)CC2)CC2=NC3=C(C=CC=C3)N2)CCCC2=CC=CN=C21 Chemical compound C.C.C.[H]C1(N(CCC2(CN)CC2)CC2=NC3=C(C=CC=C3)N2)CCCC2=CC=CN=C21 UYSVMYHBLFFIEB-UHFFFAOYSA-N 0.000 description 1
- QDQTWRFPWAHQEU-RGFWRHHQSA-N C.C.C.[H][C@@]1(N(CCCCN)CC2=NC3=C(C=CC=C3)N2)CCCC2=CC=CN=C21 Chemical compound C.C.C.[H][C@@]1(N(CCCCN)CC2=NC3=C(C=CC=C3)N2)CCCC2=CC=CN=C21 QDQTWRFPWAHQEU-RGFWRHHQSA-N 0.000 description 1
- RZFGPPKOKISGMK-UHFFFAOYSA-N C.C.C1=CC=C(CNC2CCN(CCN(CC3=NC4=CC=CC=C4N3)C3CCCC4=C3N=CC=C4)CC2)C=C1.[HH] Chemical compound C.C.C1=CC=C(CNC2CCN(CCN(CC3=NC4=CC=CC=C4N3)C3CCCC4=C3N=CC=C4)CC2)C=C1.[HH] RZFGPPKOKISGMK-UHFFFAOYSA-N 0.000 description 1
- HCFUWLXEQXWLOO-UHFFFAOYSA-N C.C.CC(C1=NC2=C(C=CC=C2)N1)N(CCCCN)C1CCCC2=C1N=CC=C2 Chemical compound C.C.CC(C1=NC2=C(C=CC=C2)N1)N(CCCCN)C1CCCC2=C1N=CC=C2 HCFUWLXEQXWLOO-UHFFFAOYSA-N 0.000 description 1
- NQWVNDKHHCSTFD-UHFFFAOYSA-N C.C.CC1=NC2=C(C=C1)CCCC2N(CCCCN)CC1=NC2=C(C=CC=C2)N1 Chemical compound C.C.CC1=NC2=C(C=C1)CCCC2N(CCCCN)CC1=NC2=C(C=CC=C2)N1 NQWVNDKHHCSTFD-UHFFFAOYSA-N 0.000 description 1
- XUDZFSIGCJVQNR-FJSYBICCSA-N C.C.CN1C(CN(CCCCN)[C@H]2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 Chemical compound C.C.CN1C(CN(CCCCN)[C@H]2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 XUDZFSIGCJVQNR-FJSYBICCSA-N 0.000 description 1
- KAEYLMNMXBOQOV-UHFFFAOYSA-N C.C.CN=C(CN)CCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 Chemical compound C.C.CN=C(CN)CCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 KAEYLMNMXBOQOV-UHFFFAOYSA-N 0.000 description 1
- IUKCEIGLMUPJOL-UHFFFAOYSA-N C.C.COC1=CC2=C(N=C1)C(N(CCCCN)CC1=NC3=CC=CC=C3N1)CCC2 Chemical compound C.C.COC1=CC2=C(N=C1)C(N(CCCCN)CC1=NC3=CC=CC=C3N1)CCC2 IUKCEIGLMUPJOL-UHFFFAOYSA-N 0.000 description 1
- ZQVLJESODGFGMA-UHFFFAOYSA-N C.C.N=C(N)CCCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 Chemical compound C.C.N=C(N)CCCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 ZQVLJESODGFGMA-UHFFFAOYSA-N 0.000 description 1
- AOOLFOZFDXTACJ-FLPKAINGSA-N C.C.NC/C(=C/CN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2)CO Chemical compound C.C.NC/C(=C/CN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2)CO AOOLFOZFDXTACJ-FLPKAINGSA-N 0.000 description 1
- AOOLFOZFDXTACJ-CNSDMJOKSA-N C.C.NC/C(=C\CN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2)CO Chemical compound C.C.NC/C(=C\CN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2)CO AOOLFOZFDXTACJ-CNSDMJOKSA-N 0.000 description 1
- SUVOAASXEQJQJR-UHFFFAOYSA-N C.C.NC1CCN(CCN(CC2=NC3=CC=CC=C3N2)C2CCCC3=C2N=CC=C3)CC1 Chemical compound C.C.NC1CCN(CCN(CC2=NC3=CC=CC=C3N2)C2CCCC3=C2N=CC=C3)CC1 SUVOAASXEQJQJR-UHFFFAOYSA-N 0.000 description 1
- JDUXTHRVZBUOIP-UHFFFAOYSA-N C.C.NCC#CCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound C.C.NCC#CCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 JDUXTHRVZBUOIP-UHFFFAOYSA-N 0.000 description 1
- HTMUFCXCNASVIL-UHFFFAOYSA-N C.C.NCC(F)(F)CCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 Chemical compound C.C.NCC(F)(F)CCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 HTMUFCXCNASVIL-UHFFFAOYSA-N 0.000 description 1
- DWJNLIMCPHLCHA-UHFFFAOYSA-N C.C.NCCC(F)(F)CN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 Chemical compound C.C.NCCC(F)(F)CN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 DWJNLIMCPHLCHA-UHFFFAOYSA-N 0.000 description 1
- FHQYHDQNXZJEEQ-UHFFFAOYSA-N C.C.NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1N=CC=N2 Chemical compound C.C.NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1N=CC=N2 FHQYHDQNXZJEEQ-UHFFFAOYSA-N 0.000 description 1
- FKDIMBFWUDDHTN-UHFFFAOYSA-N C.C.O=[N+]([O-])C1=CN=C(NCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)C=C1 Chemical compound C.C.O=[N+]([O-])C1=CN=C(NCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)C=C1 FKDIMBFWUDDHTN-UHFFFAOYSA-N 0.000 description 1
- HAJNCNOIRIDOCV-UHFFFAOYSA-N C.C1=CC=C(CNCCCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)N=C1.[H]Br.[H]Br.[H]Br.[H]Br Chemical compound C.C1=CC=C(CNCCCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)N=C1.[H]Br.[H]Br.[H]Br.[H]Br HAJNCNOIRIDOCV-UHFFFAOYSA-N 0.000 description 1
- SZUJTXSVCGFQMV-UHFFFAOYSA-N C.C1=CC=C(CNCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)N=C1 Chemical compound C.C1=CC=C(CNCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)N=C1 SZUJTXSVCGFQMV-UHFFFAOYSA-N 0.000 description 1
- AEMWZZFXDPQILZ-UHFFFAOYSA-N C.C1=CN=C(CNCCCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)N=C1 Chemical compound C.C1=CN=C(CNCCCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)N=C1 AEMWZZFXDPQILZ-UHFFFAOYSA-N 0.000 description 1
- WPENUQNFWGJAIC-UHFFFAOYSA-N C.C1=CN=C2C(=C1)CCCC2N(CCCCNC1=NC=CN1)CC1=NC2=C(C=CC=C2)N1 Chemical compound C.C1=CN=C2C(=C1)CCCC2N(CCCCNC1=NC=CN1)CC1=NC2=C(C=CC=C2)N1 WPENUQNFWGJAIC-UHFFFAOYSA-N 0.000 description 1
- QGKBNWUMPFWVQV-UHFFFAOYSA-N C.C1=CN=C2C(=C1)CCCC2N(CCCCNCC1=CNC2=C1C=CC=C2)CC1=NC2=C(C=CC=C2)N1 Chemical compound C.C1=CN=C2C(=C1)CCCC2N(CCCCNCC1=CNC2=C1C=CC=C2)CC1=NC2=C(C=CC=C2)N1 QGKBNWUMPFWVQV-UHFFFAOYSA-N 0.000 description 1
- PYNPSEIAUXRAHI-XLCHORMMSA-N C.C1=CN=C2C(=C1)CCC[C@@H]2N(CC1=NC2=C(C=CC=C2)N1)[C@@H]1CCCNC1 Chemical compound C.C1=CN=C2C(=C1)CCC[C@@H]2N(CC1=NC2=C(C=CC=C2)N1)[C@@H]1CCCNC1 PYNPSEIAUXRAHI-XLCHORMMSA-N 0.000 description 1
- AECZNGRRNIDTCK-UHFFFAOYSA-N C.CC(=O)C1=NC2=CC=CC=C2N1 Chemical compound C.CC(=O)C1=NC2=CC=CC=C2N1 AECZNGRRNIDTCK-UHFFFAOYSA-N 0.000 description 1
- IQOIWWJDHIWJOY-MKWAYWHRSA-N C.CC(C)(C)OC(=O)NC/C=C\CCl Chemical compound C.CC(C)(C)OC(=O)NC/C=C\CCl IQOIWWJDHIWJOY-MKWAYWHRSA-N 0.000 description 1
- IKGQCOMHCUQBPH-WDEXQARFSA-N C.N=C(N)N/N=C/CCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound C.N=C(N)N/N=C/CCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 IKGQCOMHCUQBPH-WDEXQARFSA-N 0.000 description 1
- HCNATHNDGOAHBA-UHFFFAOYSA-N C.N=C(N)NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound C.N=C(N)NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 HCNATHNDGOAHBA-UHFFFAOYSA-N 0.000 description 1
- NRBIROFJZIJNEX-UMYDRSSLSA-N C.NC/C(=C/CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21)CNC(=O)C1=C(Cl)C=NC=C1Cl.NC/C(=C\CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21)CNC(=O)C1=C(Cl)C=NC=C1Cl Chemical compound C.NC/C(=C/CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21)CNC(=O)C1=C(Cl)C=NC=C1Cl.NC/C(=C\CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21)CNC(=O)C1=C(Cl)C=NC=C1Cl NRBIROFJZIJNEX-UMYDRSSLSA-N 0.000 description 1
- XZJDIRGQTVPQOB-UHFFFAOYSA-N C.NCCCCN(CC1=NC=C(C2=CC=C(F)C=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound C.NCCCCN(CC1=NC=C(C2=CC=C(F)C=C2)N1)C1CCCC2=CC=CN=C21 XZJDIRGQTVPQOB-UHFFFAOYSA-N 0.000 description 1
- DVGBWPMYGGUCOA-UHFFFAOYSA-N C.O=S(=O)(NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1N=CC=C2)C1=NC=CC=C1 Chemical compound C.O=S(=O)(NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1N=CC=C2)C1=NC=CC=C1 DVGBWPMYGGUCOA-UHFFFAOYSA-N 0.000 description 1
- OYEFMWJJANORIK-UHFFFAOYSA-N C.[H]Br.[H]Br.[H]Br.[H]C1(CCCN(CC2=NC3=C(C=CC=C3)N2)C2([H])CCCC3=CC=CN=C32)CCCCN1 Chemical compound C.[H]Br.[H]Br.[H]Br.[H]C1(CCCN(CC2=NC3=C(C=CC=C3)N2)C2([H])CCCC3=CC=CN=C32)CCCCN1 OYEFMWJJANORIK-UHFFFAOYSA-N 0.000 description 1
- NCHWFZSSYRQDLG-UHFFFAOYSA-N C1=CC2=C(N=C1)C(N(CCCC1=CNC=N1)CC1=NC3=C(C=CC=C3)N1)CCC2 Chemical compound C1=CC2=C(N=C1)C(N(CCCC1=CNC=N1)CC1=NC3=C(C=CC=C3)N1)CCC2 NCHWFZSSYRQDLG-UHFFFAOYSA-N 0.000 description 1
- LBXIOIDJMPWTST-UHFFFAOYSA-N C1=CC2=C(N=C1)C(N(CCCC1=NC=CN1)CC1=NC3=C(C=CC=C3)N1)CCC2 Chemical compound C1=CC2=C(N=C1)C(N(CCCC1=NC=CN1)CC1=NC3=C(C=CC=C3)N1)CCC2 LBXIOIDJMPWTST-UHFFFAOYSA-N 0.000 description 1
- RZKGMFDJQJBRDM-UHFFFAOYSA-N C1=CC2=C(N=C1)C(N(CCN1C=CN=C1)CC1=NC3=C(C=CC=C3)N1)CCC2 Chemical compound C1=CC2=C(N=C1)C(N(CCN1C=CN=C1)CC1=NC3=C(C=CC=C3)N1)CCC2 RZKGMFDJQJBRDM-UHFFFAOYSA-N 0.000 description 1
- GIKTVGDMDALICI-UHFFFAOYSA-N C1=CC=C(CNC2CCC(N(CC3=NC4=C(C=CC=C4)N3)C3CCCC4=CC=CN=C43)CC2)N=C1.[H]Br.[H]Br.[H]Br.[H]Br Chemical compound C1=CC=C(CNC2CCC(N(CC3=NC4=C(C=CC=C4)N3)C3CCCC4=CC=CN=C43)CC2)N=C1.[H]Br.[H]Br.[H]Br.[H]Br GIKTVGDMDALICI-UHFFFAOYSA-N 0.000 description 1
- OCRVHUXDWSNVBB-UHFFFAOYSA-N C1=CC=C(CNCCCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)C=C1.[HH] Chemical compound C1=CC=C(CNCCCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)C=C1.[HH] OCRVHUXDWSNVBB-UHFFFAOYSA-N 0.000 description 1
- FTNZEQZAQWYILG-CGZQIQLYSA-N C1=CC=C(CN[C@H]2CC[C@H](N(CC3=NC4=C(C=CC=C4)N3)C3CCCC4=CC=CC=C43)CC2)C=C1 Chemical compound C1=CC=C(CN[C@H]2CC[C@H](N(CC3=NC4=C(C=CC=C4)N3)C3CCCC4=CC=CC=C43)CC2)C=C1 FTNZEQZAQWYILG-CGZQIQLYSA-N 0.000 description 1
- IAUOIPNHQUSVSR-UHFFFAOYSA-N C1=CC=C2NC(CN(C3CCC(N4CCOCC4)CC3)C3CCCC4=CC=CN=C43)=NC2=C1 Chemical compound C1=CC=C2NC(CN(C3CCC(N4CCOCC4)CC3)C3CCCC4=CC=CN=C43)=NC2=C1 IAUOIPNHQUSVSR-UHFFFAOYSA-N 0.000 description 1
- IAUOIPNHQUSVSR-RFJGZHNSSA-N C1=CC=C2NC(CN(C3CCCC4=CC=CN=C43)[C@H]3CC[C@H](N4CCOCC4)CC3)=NC2=C1 Chemical compound C1=CC=C2NC(CN(C3CCCC4=CC=CN=C43)[C@H]3CC[C@H](N4CCOCC4)CC3)=NC2=C1 IAUOIPNHQUSVSR-RFJGZHNSSA-N 0.000 description 1
- OOGPGSVKYQFKKB-UHFFFAOYSA-N C1=CN=C(CCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)C=C1 Chemical compound C1=CN=C(CCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)C=C1 OOGPGSVKYQFKKB-UHFFFAOYSA-N 0.000 description 1
- JYBPIBDANMFGOZ-RFJGZHNSSA-N C1=CN=C(CN[C@H]2CC[C@H](N(CC3=NC4=C(C=CC=C4)N3)C3CCCC4=C3N=CC=C4)CC2)N=C1 Chemical compound C1=CN=C(CN[C@H]2CC[C@H](N(CC3=NC4=C(C=CC=C4)N3)C3CCCC4=C3N=CC=C4)CC2)N=C1 JYBPIBDANMFGOZ-RFJGZHNSSA-N 0.000 description 1
- AQPJIWDSOFTIMJ-PDGQHHTCSA-N C1=CN=C2C(=C1)CCCC2N(C/C=C1/CCCNC1)CC1=NC2=C(C=CC=C2)N1.[H]Br.[H]Br.[H]Br Chemical compound C1=CN=C2C(=C1)CCCC2N(C/C=C1/CCCNC1)CC1=NC2=C(C=CC=C2)N1.[H]Br.[H]Br.[H]Br AQPJIWDSOFTIMJ-PDGQHHTCSA-N 0.000 description 1
- PHRHBBIUELWWQC-UHFFFAOYSA-N C1=CN=C2C(=C1)CCCC2N(CC1=NC2=C(C=CC=C2)N1)C1CCC(NCC2=CNC3=C2C=CC=C3)CC1 Chemical compound C1=CN=C2C(=C1)CCCC2N(CC1=NC2=C(C=CC=C2)N1)C1CCC(NCC2=CNC3=C2C=CC=C3)CC1 PHRHBBIUELWWQC-UHFFFAOYSA-N 0.000 description 1
- KSPVFXSDRFECJO-UHFFFAOYSA-N C1=CN=C2C(=C1)CCCC2N(CC1=NC2=C(C=CC=C2)N1)C1CCCNC1 Chemical compound C1=CN=C2C(=C1)CCCC2N(CC1=NC2=C(C=CC=C2)N1)C1CCCNC1 KSPVFXSDRFECJO-UHFFFAOYSA-N 0.000 description 1
- GZNXRSVITGPPLE-UHFFFAOYSA-N C1=CN=C2C(=C1)CCCC2N(CC1=NC2=C(C=CC=C2)N1)C1CCNCC1 Chemical compound C1=CN=C2C(=C1)CCCC2N(CC1=NC2=C(C=CC=C2)N1)C1CCNCC1 GZNXRSVITGPPLE-UHFFFAOYSA-N 0.000 description 1
- TVMZTRQBZRKZRZ-MONLTZSXSA-N C1=CN=C2C(=C1)CCCC2N(CC1=NC2=C(C=CC=C2)N1)[C@H]1CC[C@H](NCC2=CC3=C(C=CC=C3)N2)CC1 Chemical compound C1=CN=C2C(=C1)CCCC2N(CC1=NC2=C(C=CC=C2)N1)[C@H]1CC[C@H](NCC2=CC3=C(C=CC=C3)N2)CC1 TVMZTRQBZRKZRZ-MONLTZSXSA-N 0.000 description 1
- YNAXQZBGOFKYEI-UHFFFAOYSA-N C1=CN=C2C(=C1)CCCC2N(CCCC1=CC=NN1)CC1=NC2=C(C=CC=C2)N1 Chemical compound C1=CN=C2C(=C1)CCCC2N(CCCC1=CC=NN1)CC1=NC2=C(C=CC=C2)N1 YNAXQZBGOFKYEI-UHFFFAOYSA-N 0.000 description 1
- FEXSTQUCVPCXRP-UHFFFAOYSA-N C1=CN=C2C(=C1)CCCC2N(CCCCNC1CC1)CC1=NC2=C(C=CC=C2)N1 Chemical compound C1=CN=C2C(=C1)CCCC2N(CCCCNC1CC1)CC1=NC2=C(C=CC=C2)N1 FEXSTQUCVPCXRP-UHFFFAOYSA-N 0.000 description 1
- CEVJEMUBWSJRIY-UHFFFAOYSA-N C1=CN=C2C(=C1)CCCC2N(CCCCNCC1=CC2=C(C=CC=C2)N1)CC1=NC2=C(C=CC=C2)N1 Chemical compound C1=CN=C2C(=C1)CCCC2N(CCCCNCC1=CC2=C(C=CC=C2)N1)CC1=NC2=C(C=CC=C2)N1 CEVJEMUBWSJRIY-UHFFFAOYSA-N 0.000 description 1
- YIWUDZZUTVWTFZ-UHFFFAOYSA-N C1=CN=C2C(=C1)CCCC2NCC1=NC2=C(C=CC=C2)N1 Chemical compound C1=CN=C2C(=C1)CCCC2NCC1=NC2=C(C=CC=C2)N1 YIWUDZZUTVWTFZ-UHFFFAOYSA-N 0.000 description 1
- OORUKFHUHFCMAP-UHFFFAOYSA-N C=CCC(C)(C=O)C1=CC=CC=C1 Chemical compound C=CCC(C)(C=O)C1=CC=CC=C1 OORUKFHUHFCMAP-UHFFFAOYSA-N 0.000 description 1
- XMTZXBSMMLHWTJ-UHFFFAOYSA-N C=CCN1C(CN(CCCCN)C2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 Chemical compound C=CCN1C(CN(CCCCN)C2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 XMTZXBSMMLHWTJ-UHFFFAOYSA-N 0.000 description 1
- XMTZXBSMMLHWTJ-QFIPXVFZSA-N C=CCN1C(CN(CCCCN)[C@H]2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 Chemical compound C=CCN1C(CN(CCCCN)[C@H]2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 XMTZXBSMMLHWTJ-QFIPXVFZSA-N 0.000 description 1
- LQTBONIRGZKGML-UHFFFAOYSA-N C=CCN1C=CN=C1CN(CCCCN)C1CCCC2=C1N=CC=C2 Chemical compound C=CCN1C=CN=C1CN(CCCCN)C1CCCC2=C1N=CC=C2 LQTBONIRGZKGML-UHFFFAOYSA-N 0.000 description 1
- LQTBONIRGZKGML-SFHVURJKSA-N C=CCN1C=CN=C1CN(CCCCN)[C@H]1CCCC2=CC=CN=C21 Chemical compound C=CCN1C=CN=C1CN(CCCCN)[C@H]1CCCC2=CC=CN=C21 LQTBONIRGZKGML-SFHVURJKSA-N 0.000 description 1
- FSHCHBIQCVCYDT-QFIPXVFZSA-N C=CCN1C=CN=C1CN(CCCCNC(=O)C1=C(Cl)C=NC=C1Cl)[C@H]1CCCC2=CC=CN=C21 Chemical compound C=CCN1C=CN=C1CN(CCCCNC(=O)C1=C(Cl)C=NC=C1Cl)[C@H]1CCCC2=CC=CN=C21 FSHCHBIQCVCYDT-QFIPXVFZSA-N 0.000 description 1
- GLCVWZFNEKOPBJ-UHFFFAOYSA-N C=CCNC1(C)CCC(N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 Chemical compound C=CCNC1(C)CCC(N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 GLCVWZFNEKOPBJ-UHFFFAOYSA-N 0.000 description 1
- UIOQYFNJZGQLLN-UHFFFAOYSA-N C=CCNCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound C=CCNCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 UIOQYFNJZGQLLN-UHFFFAOYSA-N 0.000 description 1
- IOFQOIXOCGOGLB-UHFFFAOYSA-N C=COC(=O)OCC1CCN(C(=O)OC=C)C1 Chemical compound C=COC(=O)OCC1CCN(C(=O)OC=C)C1 IOFQOIXOCGOGLB-UHFFFAOYSA-N 0.000 description 1
- XMFDFSRILWBSCQ-UHFFFAOYSA-N C=COC(=O)OCC1CCN(CC2=CC=CC=C2)C1 Chemical compound C=COC(=O)OCC1CCN(CC2=CC=CC=C2)C1 XMFDFSRILWBSCQ-UHFFFAOYSA-N 0.000 description 1
- SPKKEJUHNSCZBV-UHFFFAOYSA-N C=COC(=O)OCC1CCNC1.Cl Chemical compound C=COC(=O)OCC1CCNC1.Cl SPKKEJUHNSCZBV-UHFFFAOYSA-N 0.000 description 1
- MAQCMCJQZIOEFP-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C(CN(CCCC=O)C2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 Chemical compound CC(C)(C)OC(=O)N1C(CN(CCCC=O)C2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 MAQCMCJQZIOEFP-UHFFFAOYSA-N 0.000 description 1
- WJCRQKCYLLYDHC-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C(CN(CCCCO)C2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 Chemical compound CC(C)(C)OC(=O)N1C(CN(CCCCO)C2CCCC3=CC=CN=C32)=NC2=C1C=CC=C2 WJCRQKCYLLYDHC-UHFFFAOYSA-N 0.000 description 1
- IGDVYQLIBMPCGQ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C(CN(CCN2C=CN=C2)C2CCCC3=C2N=CC=C3)=NC2=C1C=CC=C2 Chemical compound CC(C)(C)OC(=O)N1C(CN(CCN2C=CN=C2)C2CCCC3=C2N=CC=C3)=NC2=C1C=CC=C2 IGDVYQLIBMPCGQ-UHFFFAOYSA-N 0.000 description 1
- CGYAVOXVSBCDCI-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=NC(CCC=O)=C1 Chemical compound CC(C)(C)OC(=O)N1C=NC(CCC=O)=C1 CGYAVOXVSBCDCI-UHFFFAOYSA-N 0.000 description 1
- FNIMVUXGQFAIQX-UHFFFAOYSA-N CC(C)(C)OC(=O)NCCN1C=CN=C1 Chemical compound CC(C)(C)OC(=O)NCCN1C=CN=C1 FNIMVUXGQFAIQX-UHFFFAOYSA-N 0.000 description 1
- KEWKKNNTPLICCH-UHFFFAOYSA-N CC(C)N1C=CN=C1CN(CCCCN)C1CCCC2=CC=CN=C21 Chemical compound CC(C)N1C=CN=C1CN(CCCCN)C1CCCC2=CC=CN=C21 KEWKKNNTPLICCH-UHFFFAOYSA-N 0.000 description 1
- QLKBKJMVVUIQDZ-UHFFFAOYSA-N CC(CN)(CCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=CC=CN=C21)C1=CC=CC=C1 Chemical compound CC(CN)(CCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=CC=CN=C21)C1=CC=CC=C1 QLKBKJMVVUIQDZ-UHFFFAOYSA-N 0.000 description 1
- WTJLQPZYMQWSDF-UHFFFAOYSA-N CC1(N)CCC(N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 Chemical compound CC1(N)CCC(N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 WTJLQPZYMQWSDF-UHFFFAOYSA-N 0.000 description 1
- JGHHTRWNRBVLJN-UHFFFAOYSA-N CC1=C(C)C2=C(C=C1)N=C(CN(CCCCN)C1CCCC3=CC=CN=C31)N2 Chemical compound CC1=C(C)C2=C(C=C1)N=C(CN(CCCCN)C1CCCC3=CC=CN=C31)N2 JGHHTRWNRBVLJN-UHFFFAOYSA-N 0.000 description 1
- QDZVFQMBKVWCEF-UHFFFAOYSA-N CC1=C2N=C(CCl)NC2=CC=C1 Chemical compound CC1=C2N=C(CCl)NC2=CC=C1 QDZVFQMBKVWCEF-UHFFFAOYSA-N 0.000 description 1
- AXNUJYHFQHQZBE-UHFFFAOYSA-N CC1=CC=CC(N)=C1N Chemical compound CC1=CC=CC(N)=C1N AXNUJYHFQHQZBE-UHFFFAOYSA-N 0.000 description 1
- OBODMRDDPHGYRP-UHFFFAOYSA-N CC1=CNC(CN(CCCCN)C2CCCC3=CC=CN=C32)=N1 Chemical compound CC1=CNC(CN(CCCCN)C2CCCC3=CC=CN=C32)=N1 OBODMRDDPHGYRP-UHFFFAOYSA-N 0.000 description 1
- QTPGHHVZFRALBP-UHFFFAOYSA-N CCC1=CN(C)C(C=O)=N1 Chemical compound CCC1=CN(C)C(C=O)=N1 QTPGHHVZFRALBP-UHFFFAOYSA-N 0.000 description 1
- PPJZAGLTKLZYCB-UHFFFAOYSA-N CCC1=CNC(CN(CCCCN)C2CCCC3=C2N=CC=C3)=N1 Chemical compound CCC1=CNC(CN(CCCCN)C2CCCC3=C2N=CC=C3)=N1 PPJZAGLTKLZYCB-UHFFFAOYSA-N 0.000 description 1
- YTRHBVFTIXPPKR-UHFFFAOYSA-N CCCN1C=C(C)N=C1CN(CCCCN)C1CCCC2=CC=CN=C21 Chemical compound CCCN1C=C(C)N=C1CN(CCCCN)C1CCCC2=CC=CN=C21 YTRHBVFTIXPPKR-UHFFFAOYSA-N 0.000 description 1
- GQHDPGKESIMFQR-XIEYBQDHSA-N CN(C)/C=N/CCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1N=CC=C2 Chemical compound CN(C)/C=N/CCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1N=CC=C2 GQHDPGKESIMFQR-XIEYBQDHSA-N 0.000 description 1
- ZFHBTGUSSWWWTK-VPTVWWIXSA-N CN(C)/C=N/[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)CC1 Chemical compound CN(C)/C=N/[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)CC1 ZFHBTGUSSWWWTK-VPTVWWIXSA-N 0.000 description 1
- KSXGYXRHMMQMJD-UHFFFAOYSA-N CN(C)CCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound CN(C)CCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 KSXGYXRHMMQMJD-UHFFFAOYSA-N 0.000 description 1
- SIRPHJCQZYVEES-UHFFFAOYSA-N CN1C2=CC=CC=C2N=C1C=O Chemical compound CN1C2=CC=CC=C2N=C1C=O SIRPHJCQZYVEES-UHFFFAOYSA-N 0.000 description 1
- WFYJYSAVZPHLNS-UHFFFAOYSA-N CN1C=CN=C1CN(CCCCN)C1CCCC2=CC=CN=C21 Chemical compound CN1C=CN=C1CN(CCCCN)C1CCCC2=CC=CN=C21 WFYJYSAVZPHLNS-UHFFFAOYSA-N 0.000 description 1
- IJTJULJVTZPTRK-UHFFFAOYSA-N CN1CCC(NC2CCCC3=CC=CN=C32)CC1 Chemical compound CN1CCC(NC2CCCC3=CC=CN=C32)CC1 IJTJULJVTZPTRK-UHFFFAOYSA-N 0.000 description 1
- DYYBIPJEINPRQG-UHFFFAOYSA-N CN1CCCC(C=O)C1 Chemical compound CN1CCCC(C=O)C1 DYYBIPJEINPRQG-UHFFFAOYSA-N 0.000 description 1
- AUKSCMCYMDCFAB-DHBOJHSNSA-N CN1[C@H]2CCCC[C@H]21 Chemical compound CN1[C@H]2CCCC[C@H]21 AUKSCMCYMDCFAB-DHBOJHSNSA-N 0.000 description 1
- NFSWESOWDXVPBY-UHFFFAOYSA-N CNCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound CNCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 NFSWESOWDXVPBY-UHFFFAOYSA-N 0.000 description 1
- KEEMNTKIFPWXAE-DDDLIOIYSA-N CN[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 Chemical compound CN[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 KEEMNTKIFPWXAE-DDDLIOIYSA-N 0.000 description 1
- JOQJEWAXHQDQAG-UHFFFAOYSA-N COC(=O)C1=NC=CC=N1 Chemical compound COC(=O)C1=NC=CC=N1 JOQJEWAXHQDQAG-UHFFFAOYSA-N 0.000 description 1
- YFEPBWKUBQUBKL-UHFFFAOYSA-N COC(=O)CCC1=CNC=N1 Chemical compound COC(=O)CCC1=CNC=N1 YFEPBWKUBQUBKL-UHFFFAOYSA-N 0.000 description 1
- VDTYAHCPKGFEBM-UHFFFAOYSA-N COC(=O)CN(CCCC=O)N=S Chemical compound COC(=O)CN(CCCC=O)N=S VDTYAHCPKGFEBM-UHFFFAOYSA-N 0.000 description 1
- QUDXYSNKPQDYQG-UHFFFAOYSA-N COC(=O)CNCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1N=CC=C2 Chemical compound COC(=O)CNCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=C1N=CC=C2 QUDXYSNKPQDYQG-UHFFFAOYSA-N 0.000 description 1
- GPNMHGODFOWOLT-UHFFFAOYSA-N COC(CC=O)CN1C(=O)C2=C(C=CC=C2)C1=O Chemical compound COC(CC=O)CN1C(=O)C2=C(C=CC=C2)C1=O GPNMHGODFOWOLT-UHFFFAOYSA-N 0.000 description 1
- UUUCEYFQXOQMMQ-UHFFFAOYSA-N COCCN1C=CN=C1CN(CCCCN)C1CCCC2=CC=CN=C21 Chemical compound COCCN1C=CN=C1CN(CCCCN)C1CCCC2=CC=CN=C21 UUUCEYFQXOQMMQ-UHFFFAOYSA-N 0.000 description 1
- GIDJQLYMQRJVPA-UHFFFAOYSA-N COc1cccc2c1nc(CCl)[nH]2 Chemical compound COc1cccc2c1nc(CCl)[nH]2 GIDJQLYMQRJVPA-UHFFFAOYSA-N 0.000 description 1
- DKSHGVDLBMOCOR-UHFFFAOYSA-N N=C(N)N1CCC(N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)CC1 Chemical compound N=C(N)N1CCC(N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)CC1 DKSHGVDLBMOCOR-UHFFFAOYSA-N 0.000 description 1
- XGCSDDGQMBFJAR-UHFFFAOYSA-N N=C(N)NCCCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 Chemical compound N=C(N)NCCCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 XGCSDDGQMBFJAR-UHFFFAOYSA-N 0.000 description 1
- XYEMJNUPPUWBSU-UHFFFAOYSA-N N=C(N)NCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound N=C(N)NCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 XYEMJNUPPUWBSU-UHFFFAOYSA-N 0.000 description 1
- AJEPIVBDXJIJPM-HFYJOXTQSA-N N=C(N)N[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1.[HH] Chemical compound N=C(N)N[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1.[HH] AJEPIVBDXJIJPM-HFYJOXTQSA-N 0.000 description 1
- UMXIRZAMUSMJEE-UHFFFAOYSA-N NC(=O)N1CCC(N(CC2=NC3=CC=CC=C3N2)C2CCCC3=C2N=CC=C3)CC1 Chemical compound NC(=O)N1CCC(N(CC2=NC3=CC=CC=C3N2)C2CCCC3=C2N=CC=C3)CC1 UMXIRZAMUSMJEE-UHFFFAOYSA-N 0.000 description 1
- RWKIYAQSJPIZLR-UHFFFAOYSA-N NC(=O)NCCCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 Chemical compound NC(=O)NCCCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 RWKIYAQSJPIZLR-UHFFFAOYSA-N 0.000 description 1
- MDRCEYKFAQIWEG-UHFFFAOYSA-N NC(=O)NCCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 Chemical compound NC(=O)NCCN(CC1=NC2=CC=CC=C2N1)C1CCCC2=C1N=CC=C2 MDRCEYKFAQIWEG-UHFFFAOYSA-N 0.000 description 1
- NCJSVTXFSSBLRE-MHWRWJLKSA-N NC/C(/CO)=C\CN(Cc1nc2ccccc2[nH]1)C1c2ncccc2CCC1 Chemical compound NC/C(/CO)=C\CN(Cc1nc2ccccc2[nH]1)C1c2ncccc2CCC1 NCJSVTXFSSBLRE-MHWRWJLKSA-N 0.000 description 1
- ZNTUQSHTGXAILR-UHFFFAOYSA-N NC1(C2=CC=CC=C2)CCC(N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 Chemical compound NC1(C2=CC=CC=C2)CCC(N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 ZNTUQSHTGXAILR-UHFFFAOYSA-N 0.000 description 1
- LSDOZASYWOJNLX-UHFFFAOYSA-N NC1(CCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 Chemical compound NC1(CCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 LSDOZASYWOJNLX-UHFFFAOYSA-N 0.000 description 1
- APTKWRUWXZCWES-NGICGMGXSA-N NC1CCC(N(CC2=NC3=C(C=CC=C3)N2)[C@H]2CCCC3=CC=CN=C32)CC1.[H]Cl.[H]Cl.[H]Cl Chemical compound NC1CCC(N(CC2=NC3=C(C=CC=C3)N2)[C@H]2CCCC3=CC=CN=C32)CC1.[H]Cl.[H]Cl.[H]Cl APTKWRUWXZCWES-NGICGMGXSA-N 0.000 description 1
- UMAUGDNWWSJJFH-UHFFFAOYSA-N NC1CCCCC2=CC=CN=C21 Chemical compound NC1CCCCC2=CC=CN=C21 UMAUGDNWWSJJFH-UHFFFAOYSA-N 0.000 description 1
- XPEDNUVIVOSVMF-UHFFFAOYSA-N NCCC1(CN(Cc2nc(cccc3)c3[nH]2)C2c3ncccc3CCC2)CC1 Chemical compound NCCC1(CN(Cc2nc(cccc3)c3[nH]2)C2c3ncccc3CCC2)CC1 XPEDNUVIVOSVMF-UHFFFAOYSA-N 0.000 description 1
- CUOZNADPDYAGTE-UHFFFAOYSA-N NCCCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound NCCCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 CUOZNADPDYAGTE-UHFFFAOYSA-N 0.000 description 1
- VPWALYHGDSWLPU-UHFFFAOYSA-N NCCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound NCCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 VPWALYHGDSWLPU-UHFFFAOYSA-N 0.000 description 1
- AEURPJUINYQZQV-UHFFFAOYSA-N NCCCCN(CC1=NC2=C(C=CC(C(F)(F)F)=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound NCCCCN(CC1=NC2=C(C=CC(C(F)(F)F)=C2)N1)C1CCCC2=CC=CN=C21 AEURPJUINYQZQV-UHFFFAOYSA-N 0.000 description 1
- WVLHHLRVNDMIAR-UHFFFAOYSA-N NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 WVLHHLRVNDMIAR-UHFFFAOYSA-N 0.000 description 1
- CEONPQGPLILBPA-UHFFFAOYSA-N NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCCC2=CC=CN=C21 Chemical compound NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCCC2=CC=CN=C21 CEONPQGPLILBPA-UHFFFAOYSA-N 0.000 description 1
- RUNDDXJCMBJPHO-UHFFFAOYSA-N NCCCCN(CC1=NC2=C(C=CC=C2)N1CC1CC1)C1CCCC2=CC=CN=C21 Chemical compound NCCCCN(CC1=NC2=C(C=CC=C2)N1CC1CC1)C1CCCC2=CC=CN=C21 RUNDDXJCMBJPHO-UHFFFAOYSA-N 0.000 description 1
- LHWZJVGAGXYDFG-UHFFFAOYSA-N NCCCCN(CC1=NC2=C(C=CC=N2)N1)C1CCCC2=CC=CN=C21 Chemical compound NCCCCN(CC1=NC2=C(C=CC=N2)N1)C1CCCC2=CC=CN=C21 LHWZJVGAGXYDFG-UHFFFAOYSA-N 0.000 description 1
- IPQLXKIBEFLFFG-UHFFFAOYSA-N NCCCCN(CC1=NC2=C(C=CN=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound NCCCCN(CC1=NC2=C(C=CN=C2)N1)C1CCCC2=CC=CN=C21 IPQLXKIBEFLFFG-UHFFFAOYSA-N 0.000 description 1
- JFHAGESDQQUTPC-UHFFFAOYSA-N NCCCCN(CC1=NC2=C3C(=CC=C2)CCCN13)C1CCCC2=CC=CN=C21 Chemical compound NCCCCN(CC1=NC2=C3C(=CC=C2)CCCN13)C1CCCC2=CC=CN=C21 JFHAGESDQQUTPC-UHFFFAOYSA-N 0.000 description 1
- XNBZQBIMQMJRTC-UHFFFAOYSA-N NCCCCN(CC1=NC=C2CCCCN21)C1CCCC2=C1N=CC=C2 Chemical compound NCCCCN(CC1=NC=C2CCCCN21)C1CCCC2=C1N=CC=C2 XNBZQBIMQMJRTC-UHFFFAOYSA-N 0.000 description 1
- BZZXGLCJQOURCB-UHFFFAOYSA-N NCCCCN(CC1=NC=CN1)C1CCCC2=CC=CN=C21 Chemical compound NCCCCN(CC1=NC=CN1)C1CCCC2=CC=CN=C21 BZZXGLCJQOURCB-UHFFFAOYSA-N 0.000 description 1
- LBXVCYWEEQXGSV-UHFFFAOYSA-N NCCCCN(CC1=NC=CN1CC1=NC=CC=C1)C1CCCC2=CC=CN=C21 Chemical compound NCCCCN(CC1=NC=CN1CC1=NC=CC=C1)C1CCCC2=CC=CN=C21 LBXVCYWEEQXGSV-UHFFFAOYSA-N 0.000 description 1
- AIQCNANGACPILW-UHFFFAOYSA-N NCCCCN(Cc([nH]c1ccc2)nc1c2F)C1c2ncccc2CCC1 Chemical compound NCCCCN(Cc([nH]c1ccc2)nc1c2F)C1c2ncccc2CCC1 AIQCNANGACPILW-UHFFFAOYSA-N 0.000 description 1
- XIBLOKDOJYEQSC-UHFFFAOYSA-N NCCCCN(Cc1nc2ccccc2[nH]1)C(CCC1)c2c1nc[nH]2 Chemical compound NCCCCN(Cc1nc2ccccc2[nH]1)C(CCC1)c2c1nc[nH]2 XIBLOKDOJYEQSC-UHFFFAOYSA-N 0.000 description 1
- NNMQETMRHZSGJH-UHFFFAOYSA-N NCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound NCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 NNMQETMRHZSGJH-UHFFFAOYSA-N 0.000 description 1
- LGYLONLVNWTPCP-UHFFFAOYSA-N NCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound NCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 LGYLONLVNWTPCP-UHFFFAOYSA-N 0.000 description 1
- ULKDASZPXLYXGJ-CGOHPFHYSA-N NC[C@@H]1CC1CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21 Chemical compound NC[C@@H]1CC1CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21 ULKDASZPXLYXGJ-CGOHPFHYSA-N 0.000 description 1
- ULKDASZPXLYXGJ-ZYLKAMJESA-N NC[C@H]1CC1CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21 Chemical compound NC[C@H]1CC1CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21 ULKDASZPXLYXGJ-ZYLKAMJESA-N 0.000 description 1
- ULKDASZPXLYXGJ-LIHHCBPRSA-N NC[C@H]1C[C@H]1CN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound NC[C@H]1C[C@H]1CN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 ULKDASZPXLYXGJ-LIHHCBPRSA-N 0.000 description 1
- KUZZQETUCZSZQF-UCFFOFKASA-N N[C@@H](CCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C(=O)O Chemical compound N[C@@H](CCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C(=O)O KUZZQETUCZSZQF-UCFFOFKASA-N 0.000 description 1
- WJRQLLDOPDYCRG-WUQHVDQBSA-N N[C@@H]1CCCC[C@H]1N(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 Chemical compound N[C@@H]1CCCC[C@H]1N(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21 WJRQLLDOPDYCRG-WUQHVDQBSA-N 0.000 description 1
- APTKWRUWXZCWES-HTZLVSCSSA-N N[C@H]1CC[C@@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 Chemical compound N[C@H]1CC[C@@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1 APTKWRUWXZCWES-HTZLVSCSSA-N 0.000 description 1
- FEVURZGMHRYFOY-UHFFFAOYSA-N O=C(C1=C(Cl)C=NC=C1Cl)N1CCC(CN(C/C2=N/C3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)C1 Chemical compound O=C(C1=C(Cl)C=NC=C1Cl)N1CCC(CN(C/C2=N/C3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)C1 FEVURZGMHRYFOY-UHFFFAOYSA-N 0.000 description 1
- WUZAAMUZCLEMCJ-UHFFFAOYSA-N O=C(C1=C(Cl)C=NC=C1Cl)N1CCC(CNC2CCCC3=CC=CN=C32)C1 Chemical compound O=C(C1=C(Cl)C=NC=C1Cl)N1CCC(CNC2CCCC3=CC=CN=C32)C1 WUZAAMUZCLEMCJ-UHFFFAOYSA-N 0.000 description 1
- BKTDCHGMUSLMOS-UHFFFAOYSA-N O=C(C1=C(Cl)C=NC=C1Cl)N1CCC(CO)C1 Chemical compound O=C(C1=C(Cl)C=NC=C1Cl)N1CCC(CO)C1 BKTDCHGMUSLMOS-UHFFFAOYSA-N 0.000 description 1
- CKNLKAVMSOAHTB-UHFFFAOYSA-N O=C(C1=C(Cl)C=NC=C1Cl)N1CCCC(CN(C/C2=N/C3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)C1 Chemical compound O=C(C1=C(Cl)C=NC=C1Cl)N1CCCC(CN(C/C2=N/C3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)C1 CKNLKAVMSOAHTB-UHFFFAOYSA-N 0.000 description 1
- WJGKTZCVJXVWOV-UHFFFAOYSA-N O=C(C1=C(Cl)C=NC=C1Cl)N1CCCC(CO)C1 Chemical compound O=C(C1=C(Cl)C=NC=C1Cl)N1CCCC(CO)C1 WJGKTZCVJXVWOV-UHFFFAOYSA-N 0.000 description 1
- VTGITYSZVXKSSI-UHFFFAOYSA-N O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=C(O)N=C1 Chemical compound O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=C(O)N=C1 VTGITYSZVXKSSI-UHFFFAOYSA-N 0.000 description 1
- AEVJBVYSDDQHMR-UHFFFAOYSA-N O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=C2C=CC=CC2=N1 Chemical compound O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=C2C=CC=CC2=N1 AEVJBVYSDDQHMR-UHFFFAOYSA-N 0.000 description 1
- FLCKSQHWQFZDMO-UHFFFAOYSA-N O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=CC=C1 Chemical compound O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=CC=C1 FLCKSQHWQFZDMO-UHFFFAOYSA-N 0.000 description 1
- XMCWKBLEIDOMJO-UHFFFAOYSA-N O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=CC=N1 Chemical compound O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=CC=N1 XMCWKBLEIDOMJO-UHFFFAOYSA-N 0.000 description 1
- OUEPQVOAZIDDRA-UHFFFAOYSA-N O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CN=CC(Br)=C1 Chemical compound O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CN=CC(Br)=C1 OUEPQVOAZIDDRA-UHFFFAOYSA-N 0.000 description 1
- PDYAARQGBCLEOC-UHFFFAOYSA-N O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CN=N/C2=C/C=C/C=C\12 Chemical compound O=C(NCCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CN=N/C2=C/C=C/C=C\12 PDYAARQGBCLEOC-UHFFFAOYSA-N 0.000 description 1
- JSSFPNGRGJLUAP-HSZRJFAPSA-N O=C(NCCCCN(CC1=NC2=C(C=CC=C2)N1)[C@@H]1CCCC2=CC=CN=C21)C1=C(Cl)C=NC=C1Cl Chemical compound O=C(NCCCCN(CC1=NC2=C(C=CC=C2)N1)[C@@H]1CCCC2=CC=CN=C21)C1=C(Cl)C=NC=C1Cl JSSFPNGRGJLUAP-HSZRJFAPSA-N 0.000 description 1
- CMPALSHRECSAPL-QHCPKHFHSA-N O=C(NCCCCN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21)C1=CN=CC=N1 Chemical compound O=C(NCCCCN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21)C1=CN=CC=N1 CMPALSHRECSAPL-QHCPKHFHSA-N 0.000 description 1
- FBDXUWOIJQNBRA-UHFFFAOYSA-N O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=C2C=CC=CC2=NN=C1 Chemical compound O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=C2C=CC=CC2=NN=C1 FBDXUWOIJQNBRA-UHFFFAOYSA-N 0.000 description 1
- FSBIZLXPEBEJOZ-UHFFFAOYSA-N O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC2=CC=CC=C2C=N1 Chemical compound O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC2=CC=CC=C2C=N1 FSBIZLXPEBEJOZ-UHFFFAOYSA-N 0.000 description 1
- NOUOPEFWPNIWSR-UHFFFAOYSA-N O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=CC=C1 Chemical compound O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=CC=C1 NOUOPEFWPNIWSR-UHFFFAOYSA-N 0.000 description 1
- AVLLUFMEFFAWDG-UHFFFAOYSA-N O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=CC=N1 Chemical compound O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=CC=N1 AVLLUFMEFFAWDG-UHFFFAOYSA-N 0.000 description 1
- WULDYPYQIUJXQO-UHFFFAOYSA-N O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CN=C(O)C=C1 Chemical compound O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CN=C(O)C=C1 WULDYPYQIUJXQO-UHFFFAOYSA-N 0.000 description 1
- YNNMLXRRCBCWLZ-UHFFFAOYSA-N O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CN=CC(Br)=C1 Chemical compound O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CN=CC(Br)=C1 YNNMLXRRCBCWLZ-UHFFFAOYSA-N 0.000 description 1
- FSAHHTJZAFGYLL-UHFFFAOYSA-N O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=NC=CN=C1 Chemical compound O=C(NCCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=NC=CN=C1 FSAHHTJZAFGYLL-UHFFFAOYSA-N 0.000 description 1
- URXBKSYHFZMWDC-UHFFFAOYSA-N O=C(NCCCN(C/C1=N/C2=CC=CC=C2N1)C1CCCC2=CC=CN=C21)C1=C(Cl)C=NC=C1Cl Chemical compound O=C(NCCCN(C/C1=N/C2=CC=CC=C2N1)C1CCCC2=CC=CN=C21)C1=C(Cl)C=NC=C1Cl URXBKSYHFZMWDC-UHFFFAOYSA-N 0.000 description 1
- RKIIPFGHJIKGQF-UHFFFAOYSA-N O=C(NCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=C(Cl)C=NC=C1Cl Chemical compound O=C(NCCN(C/C1=N/C2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=C(Cl)C=NC=C1Cl RKIIPFGHJIKGQF-UHFFFAOYSA-N 0.000 description 1
- KJFYRXZUJTXBOS-GLDPYIMESA-N O=C(NC[C@@H]1C[C@@H]1CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21)C1=C(Cl)C=NC=C1Cl Chemical compound O=C(NC[C@@H]1C[C@@H]1CN(CC1=NC2=C(C=CC=C2)N1)[C@H]1CCCC2=CC=CN=C21)C1=C(Cl)C=NC=C1Cl KJFYRXZUJTXBOS-GLDPYIMESA-N 0.000 description 1
- DNLOJGZSKODBFO-TVHFCLLTSA-N O=C(N[C@H]1CC[C@@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1)C1=CC=CC=C1Cl.[HH] Chemical compound O=C(N[C@H]1CC[C@@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CC1)C1=CC=CC=C1Cl.[HH] DNLOJGZSKODBFO-TVHFCLLTSA-N 0.000 description 1
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N O=C(O)CCC1=CNC=N1 Chemical compound O=C(O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 description 1
- JIAKIQWNYAZUJD-UHFFFAOYSA-N O=C1CCCC2=CC=CN=C12 Chemical compound O=C1CCCC2=CC=CN=C12 JIAKIQWNYAZUJD-UHFFFAOYSA-N 0.000 description 1
- IKFGDYBQIWCSHH-UHFFFAOYSA-N O=CC1=NC=C2CCCCN21 Chemical compound O=CC1=NC=C2CCCCN21 IKFGDYBQIWCSHH-UHFFFAOYSA-N 0.000 description 1
- XCKGSACFJBCVKK-UHFFFAOYSA-N O=CCCC1=NC=CN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound O=CCCC1=NC=CN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 XCKGSACFJBCVKK-UHFFFAOYSA-N 0.000 description 1
- KUBBYTMKAVXFGA-UHFFFAOYSA-N O=S(=O)(NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=CC=C1 Chemical compound O=S(=O)(NCCCCN(CC1=NC2=C(C=CC=C2)N1)C1CCCC2=CC=CN=C21)C1=CC=CC=C1 KUBBYTMKAVXFGA-UHFFFAOYSA-N 0.000 description 1
- OXJKABMTJZANSH-RFJGZHNSSA-N O=S(=O)(N[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)CC1)C1=NC=CC=C1 Chemical compound O=S(=O)(N[C@H]1CC[C@H](N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=C2N=CC=C3)CC1)C1=NC=CC=C1 OXJKABMTJZANSH-RFJGZHNSSA-N 0.000 description 1
- SRSLGSQVHHZCMR-UHFFFAOYSA-N OCCCC1=NC=CN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound OCCCC1=NC=CN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 SRSLGSQVHHZCMR-UHFFFAOYSA-N 0.000 description 1
- YTXJLLRVKHDIRG-UHFFFAOYSA-N [Ac]NC1=CN=C(NCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)C=C1.[HH].[HH] Chemical compound [Ac]NC1=CN=C(NCCN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)C=C1.[HH].[HH] YTXJLLRVKHDIRG-UHFFFAOYSA-N 0.000 description 1
- QYVILFCVZUELEG-UHFFFAOYSA-N [H]C(=O)C1=NC=CN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound [H]C(=O)C1=NC=CN1C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 QYVILFCVZUELEG-UHFFFAOYSA-N 0.000 description 1
- VLXBTPVTHZTXBN-UHFFFAOYSA-N [H]C(=O)CCCCCNC(=O)OC(C)(C)C Chemical compound [H]C(=O)CCCCCNC(=O)OC(C)(C)C VLXBTPVTHZTXBN-UHFFFAOYSA-N 0.000 description 1
- JJSMBRBBAPMADB-UHFFFAOYSA-N [H]C(F)(CN)CCN(CC1=NC2=C(C=CC=C2)N1)C1([H])CCCC2=CC=CN=C21 Chemical compound [H]C(F)(CN)CCN(CC1=NC2=C(C=CC=C2)N1)C1([H])CCCC2=CC=CN=C21 JJSMBRBBAPMADB-UHFFFAOYSA-N 0.000 description 1
- OLRKEWWIJLOUQV-UHFFFAOYSA-N [H]C(O)(CN)CCN(CC1=NC2=C(C=CC=C2)N1)C1([H])CCCC2=CC=CN=C21 Chemical compound [H]C(O)(CN)CCN(CC1=NC2=C(C=CC=C2)N1)C1([H])CCCC2=CC=CN=C21 OLRKEWWIJLOUQV-UHFFFAOYSA-N 0.000 description 1
- JYDYHSHPBDZRPU-UHFFFAOYSA-N [H]C1(C)CCCC(N)C1 Chemical compound [H]C1(C)CCCC(N)C1 JYDYHSHPBDZRPU-UHFFFAOYSA-N 0.000 description 1
- DWDZVUKHULMHPU-UHFFFAOYSA-N [H]C1(N)CCCC(N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CC=C32)C1 Chemical compound [H]C1(N)CCCC(N(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CC=C32)C1 DWDZVUKHULMHPU-UHFFFAOYSA-N 0.000 description 1
- LZGMYDRKIKFQRC-YMXDCFFPSA-N [H][C@@]1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CCCCN1 Chemical compound [H][C@@]1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CCCCN1 LZGMYDRKIKFQRC-YMXDCFFPSA-N 0.000 description 1
- QNNRCRXWNSDGHM-DIMJTDRSSA-N [H][C@@]1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CCCN1 Chemical compound [H][C@@]1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CCCN1 QNNRCRXWNSDGHM-DIMJTDRSSA-N 0.000 description 1
- NUSVPXRFSBQBDX-OQHSHRKDSA-N [H][C@@]1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CCCNC1 Chemical compound [H][C@@]1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CCCNC1 NUSVPXRFSBQBDX-OQHSHRKDSA-N 0.000 description 1
- LZGMYDRKIKFQRC-ITUIMRKVSA-N [H][C@]1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CCCCN1 Chemical compound [H][C@]1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CCCCN1 LZGMYDRKIKFQRC-ITUIMRKVSA-N 0.000 description 1
- NUSVPXRFSBQBDX-PBVYKCSPSA-N [H][C@]1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CCCNC1 Chemical compound [H][C@]1(CN(CC2=NC3=C(C=CC=C3)N2)C2CCCC3=CC=CN=C32)CCCNC1 NUSVPXRFSBQBDX-PBVYKCSPSA-N 0.000 description 1
- VAUQEGYOOZQZBL-NRFANRHFSA-N [H][C@]1(N(CCCCNC(C)=O)CC2=NC3=CC=CC=C3N2)CCCC2=CC=CN=C21 Chemical compound [H][C@]1(N(CCCCNC(C)=O)CC2=NC3=CC=CC=C3N2)CCCC2=CC=CN=C21 VAUQEGYOOZQZBL-NRFANRHFSA-N 0.000 description 1
- XWPICWCOFAAQQW-IBGZPJMESA-N [H][C@]1(N(CCCCNC(N)=O)CC2=NC3=CC=CC=C3N2)CCCC2=CC=CN=C21 Chemical compound [H][C@]1(N(CCCCNC(N)=O)CC2=NC3=CC=CC=C3N2)CCCC2=CC=CN=C21 XWPICWCOFAAQQW-IBGZPJMESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/329,329 US20030220341A1 (en) | 2001-12-21 | 2002-12-23 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US10/457,034 US7354932B2 (en) | 2001-12-21 | 2003-06-06 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US11/301,725 US7354934B2 (en) | 2001-12-21 | 2005-12-13 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US12/036,187 US20080167341A1 (en) | 2001-12-21 | 2008-02-22 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US13/358,041 US8778967B2 (en) | 2001-12-21 | 2012-01-25 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US14/302,828 US20150038509A1 (en) | 2001-12-21 | 2014-06-12 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy |
US15/018,698 US10322111B2 (en) | 2001-12-21 | 2016-02-08 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US16/380,365 US20200000774A1 (en) | 2001-12-21 | 2019-04-10 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US17/574,674 US20220409589A1 (en) | 2001-12-21 | 2022-01-13 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34271601P | 2001-12-21 | 2001-12-21 | |
US35082202P | 2002-01-17 | 2002-01-17 | |
US10/329,329 US20030220341A1 (en) | 2001-12-21 | 2002-12-23 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US44617003A Continuation-In-Part | 2001-12-21 | 2003-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030220341A1 true US20030220341A1 (en) | 2003-11-27 |
Family
ID=26993156
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/329,329 Abandoned US20030220341A1 (en) | 2001-12-21 | 2002-12-23 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US11/301,725 Expired - Lifetime US7354934B2 (en) | 2001-12-21 | 2005-12-13 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/301,725 Expired - Lifetime US7354934B2 (en) | 2001-12-21 | 2005-12-13 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
Country Status (17)
Country | Link |
---|---|
US (2) | US20030220341A1 (no) |
EP (1) | EP1465889B1 (no) |
JP (1) | JP4556020B2 (no) |
KR (1) | KR20040068339A (no) |
CN (2) | CN102153540A (no) |
AU (1) | AU2002357379A1 (no) |
BR (1) | BRPI0215050B8 (no) |
CA (1) | CA2467718C (no) |
ES (1) | ES2623982T3 (no) |
HU (1) | HUP0402458A2 (no) |
IL (2) | IL161784A0 (no) |
MX (1) | MXPA04006136A (no) |
NO (1) | NO20042578L (no) |
NZ (1) | NZ533542A (no) |
PL (1) | PL369856A1 (no) |
RU (1) | RU2325387C2 (no) |
WO (1) | WO2003055876A1 (no) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
US20040019058A1 (en) * | 2001-12-21 | 2004-01-29 | Gary Bridger | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US20050215545A1 (en) * | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
US20050215544A1 (en) * | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
EP1613613A2 (en) * | 2003-04-11 | 2006-01-11 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
WO2006023400A2 (en) * | 2004-08-16 | 2006-03-02 | Smithkline Beecham Corporation | Chemical compounds |
WO2006022454A1 (ja) * | 2004-08-27 | 2006-03-02 | Ono Pharmaceutical Co., Ltd | 塩基性基を含有する化合物およびその用途 |
WO2006028896A3 (en) * | 2004-09-02 | 2006-04-27 | Smithkline Beecham Corp | Chemical compounds |
EP1730113A1 (en) * | 2004-03-15 | 2006-12-13 | Anormed Inc. | Process for the synthesis of a cxcr4 antagonist |
US7354934B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US20090169567A1 (en) * | 2005-11-18 | 2009-07-02 | Ono Pharmaceutical Co., Ltd., | Basic group-containing compound and use thereof |
US20090192182A1 (en) * | 2006-05-16 | 2009-07-30 | Ono Pharmaceutical Co.,Ltd. | Compound having acidic group which may be protected, and use thereof |
US20100261641A1 (en) * | 2003-04-18 | 2010-10-14 | Ono Pharmaceutical Co., Ltd. | Spiro-piperidine compounds and medicinal use thereof |
EP2397148A2 (en) | 2006-02-02 | 2011-12-21 | Allergan, Inc. | Compositions and methods for the treatment of ophthalmic disease |
WO2012041860A1 (en) | 2010-09-27 | 2012-04-05 | Bioprojet | Benzazole derivatives as histamine h4 receptor ligands |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
US10759796B2 (en) | 2016-06-21 | 2020-09-01 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
US10953003B2 (en) | 2015-12-14 | 2021-03-23 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
US11357742B2 (en) * | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1411918E (pt) | 2001-07-31 | 2012-03-06 | Genzyme Global S A R L | Métodos para mobilizar células progenitoras/estaminais |
CN1329374C (zh) * | 2004-06-09 | 2007-08-01 | 上海靶点药物有限公司 | 作为ccr5拮抗剂的化合物 |
JP2008508357A (ja) * | 2004-08-02 | 2008-03-21 | スミスクライン ビーチャム コーポレーション | 化学的化合物 |
TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
WO2006038989A1 (en) * | 2004-09-29 | 2006-04-13 | Chemocentryx, Inc. | Substituted arylamides |
UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
WO2007022523A2 (en) | 2005-08-19 | 2007-02-22 | Genzyme Corporation | Methods to enhance chemotherapy |
WO2007027999A2 (en) * | 2005-08-31 | 2007-03-08 | Smithkline Beecham Corporation | Chemical compounds |
EP2055705A4 (en) | 2006-07-31 | 2014-08-20 | Ono Pharmaceutical Co | COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF |
US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
SI2195023T1 (en) * | 2007-08-29 | 2018-07-31 | Sanofi | Humanized anti-CXCR5 antibodies, their derivatives and their uses |
CN102015717A (zh) * | 2008-03-28 | 2011-04-13 | 奥蒂瑞斯治疗公司 | 趋化因子受体调节剂 |
US8071605B2 (en) | 2008-12-12 | 2011-12-06 | Astrazeneca Ab | Piperidine compounds for use in the treatment of bacterial infections |
PA8851101A1 (es) | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
AU2011310592B2 (en) * | 2010-09-29 | 2015-01-22 | Intervet International B.V. | N-heteroaryl compounds |
ES2655443T7 (es) | 2011-12-22 | 2021-03-22 | Glycomimetics Inc | Compuestos antagonistas de E-selectina |
CA2891514C (en) | 2012-12-07 | 2020-08-25 | Glycomimetics, Inc. | Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells |
CN103694142A (zh) * | 2013-11-28 | 2014-04-02 | 浙江科技学院 | 4-N-Boc-氨基环己酮的制备方法 |
CN107108679B (zh) | 2014-12-03 | 2020-10-23 | 糖模拟物有限公司 | E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂 |
WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
US11433048B2 (en) | 2016-06-16 | 2022-09-06 | Centre National De La Recherche Scientifique | CXCR4 receptor-binding compounds useful for increasing interferon level |
US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
CN106478367B (zh) * | 2016-09-30 | 2019-01-11 | 兰州大学 | 一种合成氯胺酮的中间体化合物以及氯胺酮的合成方法 |
JP7069136B2 (ja) | 2016-10-07 | 2022-05-17 | グリコミメティクス, インコーポレイテッド | 極めて強力な多量体e-セレクチンアンタゴニスト |
AU2018225556A1 (en) * | 2017-02-21 | 2019-10-03 | Emory University | Chemokine CXCR4 receptor modulators and uses related thereto |
JP7272956B2 (ja) | 2017-03-15 | 2023-05-12 | グリコミメティクス, インコーポレイテッド | E-セレクチンアンタゴニストとしてのガラクトピラノシル-シクロヘキシル誘導体 |
US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
CN111655261A (zh) * | 2017-12-19 | 2020-09-11 | X4 制药有限公司 | 非环状cxcr4抑制剂和其用途 |
CN111566117A (zh) | 2017-12-29 | 2020-08-21 | 糖模拟物有限公司 | E-选择蛋白和半乳凝素-3的异双功能抑制剂 |
AU2019230013A1 (en) | 2018-03-05 | 2020-09-10 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
WO2019183133A1 (en) | 2018-03-19 | 2019-09-26 | Emory University | Pan-Tropic Entry Inhibitors |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
CN111777529A (zh) * | 2019-04-03 | 2020-10-16 | 复旦大学 | 一种1,4/1,5-氨基醇化合物及其制备方法 |
CA3177537A1 (en) | 2020-05-01 | 2021-11-04 | Isaiah Arkin | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents |
WO2022113069A1 (en) | 2020-11-24 | 2022-06-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents |
CN112142673B (zh) * | 2020-09-18 | 2023-06-30 | 聊城大学 | 芳基烯烃唑类衍生物及其制备方法和用途 |
CN112898178A (zh) * | 2021-01-25 | 2021-06-04 | 蚌埠产品质量监督检验研究院 | 一种N-Boc-反式-1,4-环己二胺的制备方法 |
WO2022220725A1 (en) | 2021-04-16 | 2022-10-20 | Edouard Zamaratski | Lpxh inhibitors as anti-infective agents |
US11931360B2 (en) * | 2021-06-23 | 2024-03-19 | Wayne State University | Compositions and methods relating to inhibitors of pro-inflammatory factors for treatment of cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030055054A1 (en) * | 2000-12-11 | 2003-03-20 | Tularik, Inc. | CXCR3 antagonists |
US20030069234A1 (en) * | 2001-06-06 | 2003-04-10 | Medina Julio C. | CXCR3 antagonists |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US69234A (en) * | 1867-09-24 | James w | ||
US55054A (en) * | 1866-05-29 | Improvement in lamp-chimneys | ||
US20341A (en) * | 1858-05-25 | Carpet-fastener | ||
US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
US6001826A (en) | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
JP2003524620A (ja) * | 1999-03-24 | 2003-08-19 | アノーメッド インコーポレイティド | ケモカインレセプター結合複素環化合物 |
US6683192B2 (en) * | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
PL360932A1 (en) * | 2000-09-15 | 2004-09-20 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
JP2004508421A (ja) | 2000-09-15 | 2004-03-18 | アノーメッド インコーポレイティド | ケモカインレセプター結合性ヘテロ環式化合物 |
BR0113932A (pt) * | 2000-09-15 | 2003-06-24 | Anormed Inc | Compostos heterocìclicos que se ligam ao receptor da quimiocina |
PT1411918E (pt) | 2001-07-31 | 2012-03-06 | Genzyme Global S A R L | Métodos para mobilizar células progenitoras/estaminais |
JP4556020B2 (ja) | 2001-12-21 | 2010-10-06 | ジェンザイム・コーポレーション | 高い有効性を有するケモカインレセプタ結合複素環式化合物 |
-
2002
- 2002-12-23 JP JP2003556406A patent/JP4556020B2/ja not_active Expired - Fee Related
- 2002-12-23 CA CA2467718A patent/CA2467718C/en not_active Expired - Lifetime
- 2002-12-23 KR KR10-2004-7009919A patent/KR20040068339A/ko not_active Application Discontinuation
- 2002-12-23 CN CN2011100385994A patent/CN102153540A/zh active Pending
- 2002-12-23 WO PCT/US2002/041407 patent/WO2003055876A1/en active Application Filing
- 2002-12-23 AU AU2002357379A patent/AU2002357379A1/en not_active Abandoned
- 2002-12-23 NZ NZ533542A patent/NZ533542A/en unknown
- 2002-12-23 PL PL02369856A patent/PL369856A1/xx unknown
- 2002-12-23 HU HU0402458A patent/HUP0402458A2/hu unknown
- 2002-12-23 MX MXPA04006136A patent/MXPA04006136A/es active IP Right Grant
- 2002-12-23 CN CNA028256387A patent/CN1596255A/zh active Pending
- 2002-12-23 EP EP02805977.2A patent/EP1465889B1/en not_active Expired - Lifetime
- 2002-12-23 US US10/329,329 patent/US20030220341A1/en not_active Abandoned
- 2002-12-23 BR BRPI0215050A patent/BRPI0215050B8/pt not_active IP Right Cessation
- 2002-12-23 RU RU2004122406/04A patent/RU2325387C2/ru not_active IP Right Cessation
- 2002-12-23 IL IL16178402A patent/IL161784A0/xx unknown
- 2002-12-23 ES ES02805977T patent/ES2623982T3/es not_active Expired - Lifetime
-
2004
- 2004-05-05 IL IL161784A patent/IL161784A/en active IP Right Grant
- 2004-06-18 NO NO20042578A patent/NO20042578L/no not_active Application Discontinuation
-
2005
- 2005-12-13 US US11/301,725 patent/US7354934B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030055054A1 (en) * | 2000-12-11 | 2003-03-20 | Tularik, Inc. | CXCR3 antagonists |
US20030069234A1 (en) * | 2001-06-06 | 2003-04-10 | Medina Julio C. | CXCR3 antagonists |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040019058A1 (en) * | 2001-12-21 | 2004-01-29 | Gary Bridger | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US7354934B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US20080167341A1 (en) * | 2001-12-21 | 2008-07-10 | Gary Bridger | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US10322111B2 (en) | 2001-12-21 | 2019-06-18 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US8778967B2 (en) | 2001-12-21 | 2014-07-15 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
US20060030557A1 (en) * | 2002-04-05 | 2006-02-09 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
US7863293B2 (en) | 2003-04-11 | 2011-01-04 | Genzyme Corporation | CXCR4 chemokine receptor binding compounds |
EP1613613A2 (en) * | 2003-04-11 | 2006-01-11 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
EP1613613A4 (en) * | 2003-04-11 | 2009-03-25 | Anormed Inc | CXCR4-CHEMOKIN RECEPTOR BINDING COMPOUNDS |
US20080255197A1 (en) * | 2003-04-11 | 2008-10-16 | Bridger Gary J | Cxcr4 chemokine receptor binding compounds |
US20100261641A1 (en) * | 2003-04-18 | 2010-10-14 | Ono Pharmaceutical Co., Ltd. | Spiro-piperidine compounds and medicinal use thereof |
WO2004106493A3 (en) * | 2003-05-23 | 2005-08-25 | Anormed Inc | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
WO2004106493A2 (en) * | 2003-05-23 | 2004-12-09 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
EP1730113A1 (en) * | 2004-03-15 | 2006-12-13 | Anormed Inc. | Process for the synthesis of a cxcr4 antagonist |
EP1730113A4 (en) * | 2004-03-15 | 2009-12-02 | Anormed Inc | PROCESS FOR SYNTHESIS OF A CXCR4 ANTAGONIST |
US20050215544A1 (en) * | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
US20050215545A1 (en) * | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
US7776863B2 (en) * | 2004-03-24 | 2010-08-17 | Bristol-Myers Squibb Company | Methods of treating HIV infection |
US20080045537A1 (en) * | 2004-08-16 | 2008-02-21 | Kristjan Gudmundsson | Chemical Compounds |
WO2006023400A3 (en) * | 2004-08-16 | 2006-06-08 | Smithkline Beecham Corp | Chemical compounds |
WO2006023400A2 (en) * | 2004-08-16 | 2006-03-02 | Smithkline Beecham Corporation | Chemical compounds |
US20080009495A1 (en) * | 2004-08-27 | 2008-01-10 | Ono Pharmaceutical Co., Ltd. | Compound Containing Basic Group and Use Thereof |
US7951816B2 (en) | 2004-08-27 | 2011-05-31 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
US20110142856A1 (en) * | 2004-08-27 | 2011-06-16 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
WO2006022454A1 (ja) * | 2004-08-27 | 2006-03-02 | Ono Pharmaceutical Co., Ltd | 塩基性基を含有する化合物およびその用途 |
US8822459B2 (en) | 2004-08-27 | 2014-09-02 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
US20070232615A1 (en) * | 2004-09-02 | 2007-10-04 | Kristian Gudmundsson | Chemical Compounds |
WO2006028896A3 (en) * | 2004-09-02 | 2006-04-27 | Smithkline Beecham Corp | Chemical compounds |
US8519124B2 (en) | 2005-11-18 | 2013-08-27 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
US20090169567A1 (en) * | 2005-11-18 | 2009-07-02 | Ono Pharmaceutical Co., Ltd., | Basic group-containing compound and use thereof |
US8168783B2 (en) | 2005-11-18 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
EP2407171A2 (en) | 2006-02-02 | 2012-01-18 | Allergan, Inc. | Compositions and methods for the treatment of ophthalmic disease |
EP2397148A2 (en) | 2006-02-02 | 2011-12-21 | Allergan, Inc. | Compositions and methods for the treatment of ophthalmic disease |
US8618122B2 (en) | 2006-05-16 | 2013-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
US20090192182A1 (en) * | 2006-05-16 | 2009-07-30 | Ono Pharmaceutical Co.,Ltd. | Compound having acidic group which may be protected, and use thereof |
WO2012041860A1 (en) | 2010-09-27 | 2012-04-05 | Bioprojet | Benzazole derivatives as histamine h4 receptor ligands |
US10953003B2 (en) | 2015-12-14 | 2021-03-23 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
US11357742B2 (en) * | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
US11219621B2 (en) | 2015-12-22 | 2022-01-11 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
US10759796B2 (en) | 2016-06-21 | 2020-09-01 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
US11780837B2 (en) | 2016-06-21 | 2023-10-10 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
US11306088B2 (en) | 2016-06-21 | 2022-04-19 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
US11045461B2 (en) | 2018-08-31 | 2021-06-29 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
US11672793B2 (en) | 2018-08-31 | 2023-06-13 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
Also Published As
Publication number | Publication date |
---|---|
NO20042578L (no) | 2004-09-07 |
BR0215050A (pt) | 2004-10-13 |
JP2005518397A (ja) | 2005-06-23 |
CN102153540A (zh) | 2011-08-17 |
IL161784A0 (en) | 2005-11-20 |
CA2467718C (en) | 2011-04-26 |
MXPA04006136A (es) | 2004-11-01 |
KR20040068339A (ko) | 2004-07-30 |
RU2325387C2 (ru) | 2008-05-27 |
US20060100240A1 (en) | 2006-05-11 |
WO2003055876A1 (en) | 2003-07-10 |
EP1465889B1 (en) | 2017-03-22 |
BRPI0215050B8 (pt) | 2021-05-25 |
JP4556020B2 (ja) | 2010-10-06 |
EP1465889A4 (en) | 2008-05-14 |
EP1465889A1 (en) | 2004-10-13 |
ES2623982T3 (es) | 2017-07-12 |
NZ533542A (en) | 2007-04-27 |
HUP0402458A2 (hu) | 2005-07-28 |
IL161784A (en) | 2011-07-31 |
CN1596255A (zh) | 2005-03-16 |
AU2002357379A1 (en) | 2003-07-15 |
US7354934B2 (en) | 2008-04-08 |
BR0215050B1 (pt) | 2017-11-14 |
PL369856A1 (en) | 2005-05-02 |
CA2467718A1 (en) | 2003-07-10 |
RU2004122406A (ru) | 2006-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10322111B2 (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | |
US20030220341A1 (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | |
US7629337B2 (en) | Chemokine receptor binding heterocyclic compounds | |
US6750348B1 (en) | Chemokine receptor binding heterocyclic compounds | |
AU2001294628B2 (en) | Chemokine receptor binding heterocyclic compounds | |
RU2289581C2 (ru) | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение | |
US20220409589A1 (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | |
RU2277092C2 (ru) | Гетероциклические соединения, их применение и фармацевтическая композиция для лечения состояний, опосредованных схсr4 и ccr5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ANORMED, INC., BRITISH COLUMBIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRIDGER, GARY;SKERLJ, RENATO;KALLER, AL;AND OTHERS;REEL/FRAME:014171/0639;SIGNING DATES FROM 20030508 TO 20030515 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |